BioMarin to Acquire Alesta Therapeutics for ALE1, a Potential First Oral Therapy for Hypophosphatasia
核心洞察
BioMarin Pharmaceutical Inc. has entered a definitive agreement to acquire Alesta Therapeutics, gaining the clinical-stage asset ALE1 for a $275 million upfront payment plus up to $215 million in milestone payments.
ALE1 is an orally active small molecule with the potential to be the first oral therapy for hypophosphatasia (搜索) (HPP), a rare genetic bone disease caused by ALPL (搜索) gene mutations.
ALE1 targets inorganic pyrophosphate (PPi) (搜索), the central disease metabolite, and is currently in a Phase 1/2a trial assessing safety, tolerability, and pharmacokinetics/pharmacodynamics.
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced on Aug. 18, 2026 that it has entered into a definitive agreement to acquire Alesta Therapeutics, gaining Alesta's lead clinical-stage asset, ALE1. ALE1 is an orally active, small molecule being developed for the potential treatment of hypophosphatasia (搜索) (HPP), a rare genetic bone disease caused by mutations in the ALPL (搜索) gene. The transaction has been approved by the boards of directors of both companies and is expected to be completed this quarter, subject to customary closing conditions.
ALE1 has the potential to be the first oral therapy for HPP and is currently being evaluated in an ongoing Phase 1/2a clinical trial assessing safety, tolerability and pharmacokinetics/pharmacodynamics in healthy volunteers and adults with HPP. If approved, ALE1 is expected to be the first oral therapy approach that targets the central disease metabolite, PPi (inorganic pyrophosphate), with the potential to impact both skeletal and broader manifestations of HPP through systemic correction of disease biology.
Disease Background and Unmet Need
HPP is a serious condition that can affect bone and tooth mineralization, resulting in easy or frequent bone breaks, early tooth loss, and, in adults, clinically significant muscle weakness, fatigue and pain. More than 9,000 people have been diagnosed with HPP in the U.S.; however, the disease is often underdiagnosed due to a broad spectrum of symptoms that can mimic more common conditions.
ALE1 is designed to inhibit a novel target that regulates levels of inorganic pyrophosphate (PPi) (搜索), the metabolite at the center of HPP pathology. By lowering excess PPi, ALE1 aims to restore healthier bone and mineral metabolism across the full spectrum of HPP.
Strategic Rationale
"ALE1 is a strong strategic fit for BioMarin, bringing a potential oral alternative to the injectable therapies available today for people living with HPP around the world while meaningfully strengthening our early-stage clinical pipeline," said Alexander Hardy, President and Chief Executive Officer of BioMarin. "This is exactly the kind of opportunity to address a significant unmet need that lets us compete in larger rare disease markets – adding an asset that has the potential to reach our largest addressable patient population. We plan to continue to seek these kinds of opportunities as we focus on clinical-stage innovation to drive durable growth for BioMarin."
The program will become part of BioMarin's Skeletal Conditions Business Unit following close.
"We chose to partner with BioMarin due to their deep commitment to people living with rare diseases," said Ilan Ganot, Chief Executive Officer of Alesta Therapeutics. "BioMarin's global reach, scale, and proven expertise in rare disease drug development make it an ideal partner to advance ALE1 and realize its potential as a promising treatment for patients with HPP worldwide. This acquisition is also a testament to the extraordinary work, scientific expertise, and drug development capabilities of the Alesta team."
Transaction Terms
Under the terms of the agreement, BioMarin will acquire Alesta and Alesta shareholders will receive an upfront payment of $275 million plus up to $215 million in subsequent payments upon achievement of certain development and regulatory milestones. Additionally, immediately prior to the close of BioMarin's acquisition of Alesta, Alesta will spin out all non-ALE1 assets to a new entity and former Alesta employees will transfer to the spinout entity. As a result, no Alesta employees will become employees of BioMarin in connection with the transaction.
BioMarin intends to fund the transaction with cash on hand. BioMarin expects to provide updated full-year 2026 guidance reflecting the acquisition of Alesta following the closing of the transaction. Excluding the upfront consideration, the transaction is expected to have a modestly dilutive impact on 2026 financial results.
Morgan Stanley & Co. LLC is acting as the exclusive financial advisor to BioMarin, and Jones Day is serving as legal counsel in connection with the acquisition. J.P. Morgan Securities LLC is acting as exclusive financial advisor to Alesta, and Goodwin Procter LLP and NautaDutilh N.V. are serving as legal counsel.